Top 10 Hepatitis Articles of 2018

Here are the top articles from our hepatitis coverage of the year.

Here are the top articles from our hepatitis coverage of the year.

10. Insurers Continue to Deny Coverage for Life-Saving Hepatitis C Drugs at High Rates

More than half of patients with hepatitis C are denied coverage by private insurers for life-saving treatments, while the number of patients denied coverage from public insurance also remains high.

Read more here.

9. Study Demonstrates High Stability of Hepatitis B Virus

Hepatitis B virus can remain highly infectious for several weeks at room temperature and can even maintain stability in temperatures of 4 degrees Celsius over a 9-month period.

Read more here.

8. Injection Drug Users Can Benefit from a Partially Effective Hepatitis C Vaccine

A hepatitis C virus vaccine could dramatically reduce the transmission of the virus among injection drug users, even without achieving sterilizing immunity.

Read more here.

7. FDA Updates Hepatitis C Drug Labeling to Include New Clinical Data

The FDA approved labeling revisions for hepatitis C virus treatment glecaprevir and pibrentasvir (Mavyret) to include updates to dosing recommendations, as well as safety and efficacy outcomes data from 2 clinical studies.

Read more here.

6. Global Treatment Coverage of Hepatitis B Lagging

Improved access to effective hepatitis B virus medications is needed to scale up treatment coverage among individuals with the virus, particularly in countries with a high disease burden.

Read more here.

5. New Trial to Evaluate Investigational Hepatitis C Vaccine

In an effort to develop the first successful hepatitis C virus (HCV) vaccine, Inovio Pharmaceuticals and its Korean partner GeneOne Life Science announced they have dosed the first patient in a phase 1 study evaluating an investigational vaccine against HCV infection.

Read more here.

4. Potential Hepatitis B Therapy Reduces Virus Surface Antigen in Clinical Trial

A potentially curative therapy for hepatitis B virus showed positive results in an early-phase clinical trial.

Read more here.

3. Combo Treatment Effectively Cures Hepatitis C in Liver Transplant Recipients

Researchers evaluated the safety and efficacy of treatment with sofosbuvir and velpatasvir (SOF/VEL) in adults with recurrent chronic genotype 1-4 HCV infection after liver transplant.

Read more here.

2. FDA Grants Fast Track Designation to Hepatitis B Drug

The FDA granted Fast Track designation this year to Assembly Biosciences, Inc’s novel treatment for patients with chronic hepatitis B virus infection. The drug, ABI-H0731, is the manufacturer’s lead oral HBV core inhibitor.

Read more here.

1. Study: Shortening Hepatitis C Treatment Feasible in Half of Patients

New research suggests that hepatitis C virus treatments can be shortened in half of patients receiving them without compromising efficacy, potentially leading to significant cost savings.

Read more here.